Anticancer activities of histone deacetylase inhibitors
β Scribed by Bolden, Jessica E.; Peart, Melissa J.; Johnstone, Ricky W.
- Book ID
- 109950142
- Publisher
- Nature Publishing Group
- Year
- 2006
- Tongue
- English
- Weight
- 552 KB
- Volume
- 5
- Category
- Article
- ISSN
- 1474-1776
- DOI
- 10.1038/nrd2133
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Abstract Cancer is as much an epigenetic disease as it is a genetic and cytogenetic disease. The discovery that drastic changes in DNA methylation and histone modifications are commonly found in human tumors has inspired various laboratories and pharmaceutical companies to develop and study epig
## Abstract Histone deacetylase (HDAC), inhibitors represent a new class of targeted antiβcancer agents. Several of these compounds are in clinical trials with significant activity against a spectrum of both hematologic and solid tumors at doses that are well tolerated by the patients. The HDAC inh
## Abstract Histone deacetylases (HDACs) are enzymes that catalyze the removal of acetyl groups from lysine residues in both histone and nonβhistone proteins. They play a key role in the regulation of gene transcription and many other biological processes involving chromatin. Significantly, recent